Tuesday, February 20, 2007

Failed Trial For BioMarin

BioMarin Pharmaceutical Inc. (BMRN) issued guidance for higher sales and a smaller loss, but its hypertension drug failed a mid-stage clinical trial sending the stock price plunging $2.45 to close at $18.00.

0 Comments:

Post a Comment

<< Home